Physician

Padmaja Sai, M.D.

According to 2025 Medicare claims, Padmaja Sai, M.D. (NPI: 1013002880) practices hematology/oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Flagler, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32164-5979. Sai is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833), participating under the MSSP model.

Sai's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,498 traditional Medicare patients, billed 636,432 HCPCS/CPT codes, and received $8,953,679 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,402 prescription claims across 793 beneficiaries totaling $11,238,596 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 186 claims. Open Payments data shows 16 records totaling $311. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $4,143,599 to $8,953,679. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,155,889 to $11,238,596. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $16,601 to $3,595.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,049	429,228	$4,143,599
2016	1,092	413,831	$5,003,343
2017	1,158	399,488	$5,915,215
2018	1,224	560,691	$7,183,053
2019	1,483	698,404	$7,991,395
2020	1,273	469,176	$6,147,396
2021	1,511	576,670	$8,220,306
2022	1,529	705,801	$8,452,194
2023	1,423	611,068	$7,320,928
2024	1,498	636,432	$8,953,679

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	411	2,515	$1,155,889
2016	425	2,637	$1,590,739
2017	473	3,116	$2,737,752
2018	454	2,978	$3,842,767
2019	458	2,568	$3,822,458
2020	445	2,408	$3,361,257
2021	567	3,400	$5,514,643
2022	621	3,768	$7,827,612
2023	664	3,657	$7,726,008
2024	793	4,402	$11,238,596

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	73	306	$86,092
2016	69	195	$37,951
2017	12	132	$24,256
2018	41	115	$17,114
2019	18	104	$7,799
2020	N/R	127	$7,540
2021	N/R	91	$5,830
2022	23	120	$4,446
2023	36	109	$12,666
2024	55	186	$4,598

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,031	2,904	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	487	851	$13
96372	Injection of drug or substance under skin or into muscle	453	2,030	$10
36415	Insertion of needle into vein for collection of blood sample	1,300	5,814	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,157	5,194	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	89	2,492	$1,428,343
Revlimid	Lenalidomide	87	2,254	$1,409,409
Jakafi	Ruxolitinib Phosphate	67	2,010	$1,185,020
Cabometyx	Cabozantinib S-Malate	47	1,410	$898,740
Xtandi	Enzalutamide	48	1,440	$644,624

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	13	66	$2,312
J8999	Prescription drug, oral, chemotherapeutic, nos	N	12	27	$887
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	16	42	$784
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	14	51	$614

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	16	$311	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Padmaja Sai, M.D.?

Tedicare shows public-source Medicare data for Padmaja Sai, M.D. (NPI 1013002880), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Padmaja Sai, M.D. have ACO affiliation data?

Padmaja Sai, M.D. is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833).

What billing organization is linked to Padmaja Sai, M.D.?

Padmaja Sai, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Padmaja Sai, M.D. have Open Payments data?

Padmaja Sai, M.D. has 16 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.